In support of this notion, histone deacetylase (HDAC) inhibition elicits metabolic reprogramming by targeting super-enhancers in glioblastoma, and combination treatment with HDAC and fatty acid oxidation (FAO) inhibitors exhibits a better therapeutic potential [42]. The gene discussed is HDAC9; the disease is glioblastoma.